Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors

Current Opinion in Oncology

Volumn 24, Issue 4, 2012, Pages 409-413

  Tothova, Zuzana ^a   Wagner, Andrew J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

anaplastic lymphoma kinase; crizotinib; inflammatory myofibroblastic tumors

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; AP 26113; ASP 3026; CRIZOTINIB; HYBRID PROTEIN; LDK 378; NUCLEOPHOSMIN; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME REARRANGEMENT; DRUG DOSE ESCALATION; ENZYME ACTIVATION; ENZYME INHIBITION; FUSION GENE; GENE DOSAGE; GENE LOCUS; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LUNG ADENOCARCINOMA; NEUROBLASTOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CELL GRANULOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; RHABDOMYOSARCOMA; TREATMENT RESPONSE;

GENE FUSION; GRANULOMA, PLASMA CELL; HUMANS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84862129436     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328354c155     Document Type: Review

References (34)

1. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol 2008; 61:428-437. (Pubitemid 351518223)
2. Marino-Enriquez A, Wang WL, Roy A, et al. Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol 2011; 35:135-144.
3. Griffin CA, Hawkins AL, Dvorak C, et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999; 59:2776-2780. (Pubitemid 29283106)
4. Matsubara O, Tan-Liu NS, Kenney RM, et al. Inflammatory pseudotumors of the lung: progression from organizing pneumonia to fibrous histiocytoma or to plasma cell granuloma in 32 cases. Hum Pathol 1988; 19:807-814.
5. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263:1281-1284. (Pubitemid 24107549)
6. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009; 9:331-356.
7. Kelleher FC, McDermott R. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer 2010; 46:2357-2368.
8. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000; 157:377-384. (Pubitemid 30627557)
9. Ma Z, Hill DA, Collins MH, et al. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2003; 37:98-105. (Pubitemid 36417927)
10. Bridge JA, Kanamori M, Ma Z, et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001; 159:411-415. (Pubitemid 32751070)
11. Panagopoulos I, Nilsson T, Domanski HA, et al. Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer 2006; 118:1181-1186. (Pubitemid 43185605)
12. Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 2007; 31:509-520. (Pubitemid 46569034)
13. Chan JK, Cheuk W, Shimizu M. Anaplastic lymphoma kinase expression in inflammatory pseudotumors. Am J Surg Pathol 2001; 25:761-768. (Pubitemid 32496865)
14. Takeuchi K, Soda M, Togashi Y, et al. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clin Cancer Res 2011; 17:3341-3348.
15. Siminovich MH, Galluzzo Mutti ML, Lopez JM, et al. Inflammatory myofibroblastic tumor of the lung in children: anaplastic lymphoma kinase (ALK) expression and clinico-pathological correlation. Pediatr Dev Pathol 2012. [Epub ahead of print]
16. Yuan Y, Liao YM, Hsueh CT, et al. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2012; 4:16.
17. Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010; 363:1727-1733.
18. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmall-cell lung cancer. N Engl J Med 2010; 363:1693-1703.
19. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced nonsmall-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12:1004-1012.
20. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363:1734-1739.
21. Sasaki T, Okuda K, Zheng W, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010; 70:10038-10043.
22. Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011; 71:6051-6060.
23. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in nonsmall cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011; 108:7535-7540.
24. Li N, Michellys PY, Kim S, et al. Activity of a potent and selective phase I ALK inhibitor LDK378 in na?̈ve and crizotinib-resistant preclinical tumor models. In: Proceedings of the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 12-16 November 2011; San Francisco, California. Philadelphia (PA): AACR. Mol Cancer Ther 2011; 10:Abstract 232.
25. Kuromitsu S, Mori M, Shimada I, et al. Antitumor activities of ASP3026 against EML4-ALK dependent tumor models. In: Proceedings of the 2011 AACRNCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 12-16 November 2011; San Francisco, California. Philadelphia (PA): AACR. Mol Cancer Ther 2011. p. 10.
26. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455:975-978.
27. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455:930-935.
28. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455:971-974.
29. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455:967-970.
30. Sugawara E, Togashi Y, Kuroda N, et al. Identification of anaplastic lymphoma kinase fusions in renal cancer: Large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer method. Cancer 2012. [Epub ahead of print]
31. Van Gaal JC, Flucke UE, Roeffen MH, et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J Clin Oncol 2012; 30:308-315.
32. Robertson FM, Petricoin EF, Chu K, et al. Gene amplification of anaplastic lymphoma kinase in inflammatory breast cancer. In: Proceedings of the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 12-16 November 2011; San Francisco, California. Philadelphia (PA): AACR. Mol Cancer Ther 2011. p. 11.
33. Marino-Enriquez A, Ou WB, Weldon CB, et al. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma. Genes Chromosomes Cancer 2011; 50:146-153.
34. Debelenko LV, Raimondi SC, Daw N, et al. Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum. Mod Pathol 2011; 24:430-442.